What is it about?
Rotavirus is a virus that causes diarrhea and vomiting in infants and leads to approximately 210,00 deaths annually. Oral Rotavirus vaccines are available to prevent rotavirus infections in infants and children. Numerous oral vaccines incorporate alkaline buffering agents into vaccine from degrading in the stomach, which is known to be acidic. Due to Rotavac's unique characteristics, we hypothesized that such a buffer is not required. We conducted a study to evaluate if the role of the buffer plays an influential role in the immune response produced by the body towards Rotavac.
Featured Image
Why is it important?
Based on our findings, Rotavac is the only licensed vaccine rotavirus vaccine that does not contain a buffer. Thus, reducing the dosage amount of the vaccine to 0.5 mL (5 drops). This reduction in dosage decreases the amount of space required in refrigerators for storage and enables the vaccine to be administered accurately by health staff.
Perspectives
This is the first publication that supports the notion of licensed rotavirus vaccines not requiring a buffer. This vaccine is now available internationally and is being supplied to the World Health Organization.
raches ella
Bharat Biotech International Limited
Read the Original
This page is a summary of: A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India, Human Vaccines & Immunotherapeutics, March 2018, Taylor & Francis,
DOI: 10.1080/21645515.2018.1450709.
You can read the full text:
Contributors
The following have contributed to this page
